| Active substance | Retifanlimab |
| Holder | Incyte Biosciences Benelux BV |
| Status | Running |
| Indication | first-line treatment of adult patients with metastatic or with inoperable locally recurrent Squamous Carcinoma of the Anal Canal (SCAC) with retifanlimab in combination with carboplatin and paclitaxel |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 31/07/2025 |